Tae Il Kim | Oncology | Research Excellence Award

Published on by NESIN Awards

Prof. Tae Il Kim | Oncology | Research Excellence Award

Professor | Yonsei University College of Medicine | South Korea

Dr. Tae Il Kim is a distinguished researcher at Yonsei University College of Medicine in Seoul, South Korea, specializing in gastroenterology, colorectal cancer, and precision oncology. He has authored 337 Documents, which have received 8,659 citations, and holds an h-index of 46, reflecting his substantial global impact in biomedical and clinical research. Dr. Kim’s work focuses on translational and clinical studies that advance the understanding, diagnosis, and treatment of colorectal cancer and related gastrointestinal disorders. His notable contributions include elucidation of the HER2-ELF3-KRAS signaling axis in KRASG13D colorectal cancer, development of a novel risk score for 30-day adverse events following colonoscopy in older adults, and identification of circulating RNA biomarkers associated with the adenoma–carcinoma sequence. He has also pioneered multi-omic and machine learning-based approaches for precision oncology, including the CAN-Scan platform and non-invasive screening tools for early detection, as well as genome-wide association studies on nonhereditary colorectal polyposis and its recurrence. Dr. Kim collaborates extensively with over 800 co-authors across diverse disciplines and institutions, demonstrating a commitment to interdisciplinary and international research networks. His work has significantly contributed to improved patient care, early diagnosis, personalized therapeutic strategies, and the translation of scientific discoveries into clinical practice. By integrating innovation, rigorous research, and collaboration, Dr. Kim continues to shape the future of gastroenterology and oncology, enhancing global knowledge, advancing precision medicine, and elevating the visibility of Korean medical research on the international stage, with a tangible societal impact through better patient outcomes and public health advancements.

Profiles: Scopus | ORCID

Featured Publications

Kim, T. I., et al. (2025). Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes: Cellular and Molecular Biology. British Journal of Cancer. (Citations: 3)

Kim, T. I., et al. (2025). Circulating RNA markers associated with adenoma–carcinoma sequence in colorectal cancer. International Journal of Molecular Sciences. (Citations: 3)

Kim, T. I., et al. (2025). CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Reports Medicine. (Citations: 2)

Kim, T. I., et al. (2025). Machine learning-enabled non-invasive screening of tumor-associated circulating transcripts for early detection of colorectal cancer. International Journal of Molecular Sciences. (Citations: 2)

Kim, T. I., et al. (2025). Identification of genetic factors related with nonhereditary colorectal polyposis and its recurrence through genome-wide association study. Journal of Gastroenterology and Hepatology Australia.(Citations: 1)

Sara Mogedano Cruz | Oncology | Young Scientist Award

Published on by NESIN Awards

Mrs. Sara Mogedano Cruz | Oncology | Young Scientist Award

Universidad Europea de Madrid | Spain

Sara Mogedano-Cruz is a developing scholar in the field of biomedical and clinical sciences, affiliated with the Universidad Europea de Madrid in Villaviciosa de Odón, Spain, where she focuses on anatomical variability, anthropometric modeling, and evidence-based approaches to improving procedural safety. Her research emphasizes the integration of quantitative anatomical assessment into clinical workflows to enhance precision, reduce risk, and support safer invasive procedures. She has contributed to interdisciplinary studies that bridge anatomy, physiotherapy, clinical biomechanics, and medical engineering, strengthening the translation of scientific evidence into patient-centered practice. Her notable work includes the publication Predicting Median Nerve Depth from Anthropometric Features: A Tool for Safer Invasive Procedures, which examines how anthropometric predictors can guide clinicians in estimating nerve depth more accurately. Additionally, she co-authored the case report Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy, reflecting her engagement with clinically meaningful interventions and her involvement in research that intersects neuromuscular assessment and oncology-related neuropathy. With five indexed documents and collaborations with national and international researchers, her scholarship is gaining visibility, supported by a growing citation record that underscores the relevance of her work to emerging clinical methodologies. Through her commitment to methodological rigor and multidisciplinary inquiry, she aims to advance innovations that connect anatomical science, clinical decision-making, and technological development for improved patient outcomes and broader societal benefit. Sara Mogedano-Cruz’s academic influence and research productivity are reflected in her metrics: 18 citations, 5 documents, and an h-index of 1.

Profiles: Scopus | ORCID

Featured Publication

1. Mogedano-Cruz, S., González-de-la-Flor, Á., Rodríguez-Anadón, C., Bohn, L., Villafañe, J., & Romero-Morales, C. (2025). Predicting median nerve depth from anthropometric features: A tool for safer invasive procedures. PLoS ONE, 20(8), e0330383. (Cited by: 1).

Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Published on by NESIN Awards

Assoc. Prof. Dr. Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Associate Professor | Rayat-Bahra University | India  

Assoc. Prof. Dr. Vivek Kumar Garg is an accomplished academic and researcher in the field of neurology and medical biochemistry, currently serving as Associate Professor at Rayat Bahra University, Mohali, with prior academic and research appointments at Chandigarh University, PGIMER Chandigarh, and the Institute of Genomics and Integrative Biology, New Delhi. He earned his Ph.D. in Neurology from PGIMER, Chandigarh, in 2018, focusing on the pharmacogenetics of antiepileptic drug-related adverse reactions in the North Indian population, following his M.Sc. in Medical Biochemistry (2008) and B.Sc. in Human Anatomy, Physiology, and Biochemistry (2006) from BFUHS, Faridkot. His professional experience spans teaching, research, and clinical diagnostics, including roles as Research Scientist in the COVID-19 laboratory at Punjab Biotechnology Incubator and as Demonstrator in Biochemistry at Government Medical College and Hospital, Chandigarh. His research interests include pharmacogenomics, neurodegenerative disorders, drug-induced adverse reactions, and biomarker discovery for complex diseases such as epilepsy, Alzheimer’s disease, and cancer. He is skilled in advanced research methodologies, including PCR, real-time PCR, ELISA, auto-analyzers, flame photometry, and biostatistical analysis, with strong expertise in both laboratory techniques and clinical research design. Dr. Garg has published extensively in peer-reviewed and indexed journals such as Human Immunology and Asian Journal of Psychiatry, and has also served as guest editor and editorial board member for international journals. He has guided multiple M.Sc. dissertations, delivered lectures, conducted workshops, and contributed as an examiner, BOS member, and research coordinator, reflecting his leadership in academia. His awards and honors include the prestigious ICMR Junior Research Fellowship, National Education Excellence Achievers Award, and multiple institutional recognitions as a transformative researcher and research luminary. With 1,757 citations, 90 documents, and an h-index of 18, Dr. Garg has established a strong academic footprint, reflecting both the impact of his research and his growing influence in biomedical sciences.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

  1. Kashyap, D., Garg, V. K., & Goel, N. (2021). Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. Advances in Protein Chemistry and Structural Biology, 125, 73–120. Cited by: 411

  2. Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., … & Garg, V. K. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. Cited by: 405

  3. Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., … (2019). Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules, 9(5), 174. Cited by: 257

  4. Kashyap, D., Sharma, A., Tuli, H. S., Sak, K., Garg, V. K., Buttar, H. S., Setzer, W. N., … (2018). Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function. Journal of Functional Foods, 48, 457–471. Cited by: 134

  5. Aggarwal, V., Kashyap, D., Sak, K., Tuli, H. S., Jain, A., Chaudhary, A., Garg, V. K., … (2019). Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. International Journal of Molecular Sciences, 20(3), 656. Cited by: 123

Boya Guan | Medical Oncology | Best Researcher Award

Published on by NESIN Awards

Prof. Boya Guan | Medical Oncology | Best Researcher Award

Pharmacist-in-charge​ at Tianjin Hospital | China

Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.

Professional Profiles

Scopus Profile | ORCID Profile 

Education

Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.

Experience

With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.

Research Interest

Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.

Awards and Honors

Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.

Research Skills

Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.

Publication Top Notes

Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025

Conclusion

Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.

Tanmay Kulkarni | Cancer Biology | Best Researcher Award

Published on by NESIN Awards

Dr. Tanmay Kulkarni | Cancer Biology | Best Researcher Award

Assistant Professor at Mayo Clinic Florida, United States

Dr. Tanmay Kulkarni is a highly accomplished research professional with over 12 years of publication experience and 7+ years in academic and clinical research settings, currently serving as Assistant Professor and Research Associate at Mayo Clinic. With a multidisciplinary background in electrical engineering and biomedical sciences, he has authored numerous high-impact publications and led innovative projects involving nanomechanical analysis, tumor microenvironments, and biosensing systems. His contributions include serving as a guest editor for special issues, submitting NIH and DoD grants, and mentoring young researchers. Dr. Kulkarni’s technical expertise spans advanced microscopy, data analysis, and scientific writing. His leadership in research, coupled with editorial and peer-review roles across multiple journals, showcases his influence in the scientific community. Recognized with awards and invited presentations, his dedication to translational science and academic excellence positions him as a strong candidate for the Best Researcher Award. He exemplifies innovation, collaboration, and impactful scientific contribution.

Professional Profile 

Education🎓

Dr. Tanmay Kulkarni holds a robust academic background in electrical and electronics engineering, which laid the foundation for his multidisciplinary research career. He earned his Doctor of Philosophy (Ph.D.) in Electrical Engineering from the University of Maryland, Baltimore County (UMBC) in 2017, where his doctoral work focused on developing a self-powered biosensing system capable of simultaneously sensing glucose and powering microelectronic devices—a novel concept with potential clinical applications. Prior to that, he completed his Master of Science (M.S.) in Electrical Engineering from UMBC in 2014, where he was involved in collaborative biomedical imaging research analyzing adipose tissue distribution in hyperglycemic baboons. He began his academic journey with a Bachelor of Engineering in Electronics and Telecommunication from Mumbai University in 2012. Throughout his educational path, Dr. Kulkarni has consistently demonstrated strong analytical, experimental, and collaborative skills, integrating engineering principles with biomedical applications, which continue to drive his success in translational research.

Professional Experience📝

Dr. Tanmay Kulkarni brings extensive professional experience spanning over seven years in top-tier research environments, primarily at the Mayo Clinic in Jacksonville, Florida. Currently serving as an Assistant Professor and Research Associate, he leads projects focused on tumor microenvironments, cell-matrix interactions, and nanomechanical analysis using advanced microscopy techniques. He previously held roles as Senior Research Fellow and Research Fellow, where he contributed to groundbreaking studies involving atomic force microscopy, Raman spectroscopy, and biosensor development. Dr. Kulkarni has authored and co-authored numerous high-impact publications, presented at prestigious symposia, and submitted competitive NIH and DoD grants as a principal and co-investigator. His leadership extends to editorial roles, including guest editor for special journal issues and reviewer for several high-impact journals. He has also mentored students through programs like SPARK and SURF, reflecting his commitment to scientific mentorship. His career reflects a balance of innovation, collaboration, and academic excellence in translational biomedical research.

Research Interest🔎

Dr. Tanmay Kulkarni’s research interests lie at the intersection of engineering, biology, and medicine, with a strong focus on translational applications. His primary areas of interest include tumor microenvironment (TME) dynamics, nanomechanical characterization of biological tissues, biosensor development, and cell-extracellular matrix interactions. He is particularly passionate about leveraging advanced microscopy techniques—such as atomic force microscopy, confocal imaging, and Raman spectroscopy—to explore disease mechanisms at the molecular and cellular level. Dr. Kulkarni is also deeply involved in developing self-powered biosensing systems that integrate biofuel cells for real-time health monitoring and energy-efficient diagnostics. His recent work focuses on understanding the immunological landscape in cancer biopsies, designing biomaterials for drug delivery, and identifying extracellular vesicle signatures for neurodegenerative and metabolic diseases. By combining quantitative engineering tools with biological insight, Dr. Kulkarni aims to contribute to early disease detection, targeted therapy, and personalized medicine, making meaningful strides in biomedical engineering and clinical research.

Award and Honor🏆

Dr. Tanmay Kulkarni has received several prestigious awards and honors that reflect his outstanding contributions to biomedical research and scientific innovation. He was honored with the Outstanding Abstract Certificate at the 9th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk in 2022, recognizing the significance and impact of his research on immune-tumor interactions. Additionally, he earned the Best Poster Presentation Award at the same symposium, further highlighting the excellence of his scientific communication. Dr. Kulkarni’s inclusion in Marquis Who’s Who in November 2024 acknowledges his professional achievements and influence in the scientific community. His appointment as Guest Editor for special issues in leading journals and his roles on editorial and reviewer boards—including Frontiers in Bioengineering and Biotechnology, European Journal of Biophysics, and Biosensors Journal—underscore his leadership and service to the field. These accolades collectively reflect his innovation, academic rigor, and dedication to advancing translational biomedical science.

Research Skill🔬

Dr. Tanmay Kulkarni possesses a diverse and advanced set of research skills that support his multidisciplinary investigations in biomedical science and engineering. He is highly proficient in designing and conducting complex experiments, particularly those involving atomic force microscopy, confocal imaging, Raman spectroscopy, and biomaterials characterization. Dr. Kulkarni is skilled in statistical data analysis, figure preparation, and manuscript development, having authored numerous high-impact publications. His technical expertise extends to software tools such as GraphPad Prism, Origin, ImageJ, MATLAB, Biorender, and Endnote, which he uses for data visualization and scientific reporting. He is experienced in NIH grant writing and has successfully submitted multiple research proposals as a principal and co-investigator. Furthermore, he is adept at scientific editing, proofreading, and adhering to journal-specific guidelines, often serving as a reviewer and editorial board member for reputed journals. Dr. Kulkarni’s strengths also include interdisciplinary collaboration and mentoring, enabling impactful research across engineering, biology, and clinical domains.

Conclusion💡

Dr. Tanmay Kulkarni is an excellent candidate for the Best Researcher Award. His outstanding publication record, multidisciplinary expertise, editorial leadership, and sustained scientific productivity make him highly deserving of this recognition. With continued focus on broader impact and recognition, his profile will only grow stronger. His application would stand out among nominees due to its depth, breadth, and alignment with innovation and academic excellence.

Publications Top Noted✍️

  • Slaughter, G. & Kulkarni, T. (2015)
    Title: Enzymatic glucose biofuel cell and its application
    Journal: Journal of Biochips & Tissue Chips, 5(1), 1
    Citations: 104

  • Slaughter, G. & Kulkarni, T. (2016)
    Title: A self-powered glucose biosensing system
    Journal: Biosensors and Bioelectronics, 78, 45-50
    Citations: 102

  • Kulkarni, T. & Slaughter, G. (2016)
    Title: Application of semipermeable membranes in glucose biosensing
    Journal: Membranes, 6(4), 55
    Citations: 84

  • Slaughter, G. & Kulkarni, T. (2017)
    Title: Highly selective and sensitive self-powered glucose sensor based on capacitor circuit
    Journal: Scientific Reports, 7(1), 1471
    Citations: 76

  • Kulkarni, T. & Slaughter, G. (2017)
    Title: Characteristics of two self-powered glucose biosensors
    Journal: IEEE Sensors Journal, 17(12), 3607–3612
    Citations: 34

  • Slaughter, G. & Kulkarni, T. (2016)
    Title: Fabrication of palladium nanowire array electrode for biofuel cell application
    Journal: Microelectronic Engineering, 149, 92–96
    Citations: 33

  • Kulkarni, T., Tam, A., Mukhopadhyay, D., & Bhattacharya, S. (2019)
    Title: AFM study: Cell cycle and probe geometry influences nanomechanical characterization of Panc1 cells
    Journal: Biochimica et Biophysica Acta (BBA) – General Subjects, 1863(5), 802–812
    Citations: 29

  • Arthur, P., Kandoi, S., Sun, L., Kalvala, A., Kutlehria, S., Bhattacharya, S., … (Kulkarni, T.) (2023)
    Title: Biophysical, molecular and proteomic profiling of human retinal organoid-derived exosomes
    Journal: Pharmaceutical Research, 40(4), 801–816
    Citations: 28

  • Slaughter, G. & Kulkarni, T. (2019)
    Title: Detection of human plasma glucose using a self-powered glucose biosensor
    Journal: Energies, 12(5), 825
    Citations: 23

  • Kulkarni, T. & Slaughter, G. (2016)
    Title: Self-powered glucose biosensor operating under physiological conditions
    Conference: 2016 IEEE SENSORS, 1–3
    Citations: 22

  • Kulkarni, T., Angom, R.S., Das, P., Bhattacharya, S., & Mukhopadhyay, D. (2019)
    Title: Nanomechanical insights: Amyloid beta oligomer-induced senescent brain endothelial cells
    Journal: BBA – Biomembranes, 1861(12), 183061
    Citations: 21

Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by NESIN Awards

Assoc. Prof. Dr. Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Erzincan Üniversitesi, Turkey

Dr. Ahmet Altay is an accomplished researcher and academic in the field of chemistry, specializing in biochemistry, medicinal chemistry, and interdisciplinary sciences. With a strong background in natural product chemistry and anticancer drug discovery, he has contributed significantly to the scientific community through his research on antioxidants, cytotoxic agents, and enzyme inhibition. His extensive publication record in high-impact SCI-Expanded journals highlights his expertise in experimental and computational studies. Currently serving as an Associate Professor at Erzincan Binali Yıldırım University, Dr. Altay continues to push the boundaries of chemical and biochemical research, focusing on novel therapeutic compounds and their biological applications.

Professional Profile 

Education

Dr. Ahmet Altay earned his Ph.D. in Biochemistry from Middle East Technical University (METU), Turkey, in 2015. His doctoral research focused on the antioxidant and cytotoxic properties of Salvia fruticosa M., as well as its effects on cytochrome P450 enzymes and antioxidant gene expression in colon cancer cells.

Professional Experience

Dr. Altay has been a faculty member at Erzincan Binali Yıldırım University since 2016. He started as an Assistant Professor (2016-2018), was promoted to Associate Professor in 2020, and has since been actively involved in research and teaching. His work spans multiple disciplines within chemistry and biochemistry, with a strong focus on drug discovery and molecular interactions. His contributions include supervising graduate students, securing research grants, and collaborating on international scientific projects.

Research Interests

Dr. Ahmet Altay’s research interests lie at the intersection of biochemistry, medicinal chemistry, and pharmacology, with a particular focus on drug discovery and natural product chemistry. His work extensively explores the antioxidant, anticancer, and enzyme-inhibitory properties of bioactive compounds derived from medicinal plants. He is also deeply engaged in molecular docking studies to understand drug-receptor interactions at a computational level. Additionally, his research investigates apoptosis mechanisms, oxidative stress-related disorders, and the modulation of key metabolic pathways in cancer and neurodegenerative diseases. By integrating experimental and computational approaches, Dr. Altay aims to develop novel therapeutic agents that can target cancer, microbial infections, and enzyme-related disorders. His interdisciplinary research combines chemical synthesis, molecular modeling, and pharmacological evaluation to provide innovative solutions in biomedical sciences.

Awards and Honors

Dr. Ahmet Altay has received multiple awards and recognitions for his outstanding contributions to scientific research and academia. His excellence in publishing high-impact research has been acknowledged with best paper awards and recognitions from international conferences and scientific organizations. He has been honored with research grants and funding support for his projects on natural product chemistry and drug discovery. As an active academic, he has also received accolades for his contributions to student mentorship and scientific collaboration. His efforts in cancer research and enzyme inhibition studies have been recognized by national and international institutions. Additionally, his role as a peer reviewer and editorial board member in prestigious scientific journals highlights his expertise and influence in the field. These awards and honors underscore his dedication to advancing biomedical and pharmaceutical sciences.

Research Skills

Dr. Ahmet Altay possesses a diverse set of research skills spanning experimental and computational methodologies. His expertise includes the isolation and structural characterization of bioactive natural products using advanced chromatographic and spectroscopic techniques such as HPLC, GC-MS, and NMR. He is highly proficient in molecular docking, molecular dynamics simulations, and in silico drug design to predict ligand-target interactions. His skills in biochemical assays enable the evaluation of antioxidant, antimicrobial, and anticancer activities of synthetic and natural compounds. Additionally, he has extensive experience in enzyme kinetics, apoptosis studies, and gene expression analysis using RT-PCR and Western blot techniques. His interdisciplinary knowledge allows him to integrate synthetic chemistry, pharmacology, and bioinformatics to address complex biomedical challenges. Dr. Altay’s strong analytical skills, coupled with his experience in mentoring and collaboration, make him a leading researcher in his field.

Conclusion

Dr. Ahmet Altay is a strong candidate for the Best Researcher Award due to his high research output, international collaborations, and contributions to anticancer and biochemical research. To enhance his profile further, he could focus on leading large-scale projects, securing more grants, and publishing in top-tier journals. Nonetheless, his achievements make him a compelling nominee for this award.

Publications Top Noted

  • Title: Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

    • Authors: Emine Karaca Sulukoğlu, Şükran Günaydın, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2024
    • Citation: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • DOI: 10.1007/s00210-024-02980-5

  • Title: The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

    • Authors: Esma Kübra Kağan Yeniçeri, Ahmet Altay
    • Year: 2024
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1376859

  • Title: Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

    • Authors: Şükran Günaydın, Emine Karaca Sulukoğlu, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4505

  • Title: Effect of evernic acid on human breast cancer MCF‐7 and MDA‐MB‐453 cell lines via thioredoxin reductase 1: A molecular approach

    • Authors: Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4451

  • Title: In Vitro Cytotoxic Evaluation of a Silver(I) Complex Including Non-Steroidal Anti-Inflammatory Drug Niflumic Acid and 3-Picoline on Human-Derived Cancer Cell Lines

    • Authors: Sema Çağlar, Ahmet Altay, Bülent Çağlar, Esma Kübra Kağan Yeniçeri, Betül Harurluoğlu
    • Year: 2022
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1130634

  • Title: A Biochemical Approach for Hedysarum candidissimum from Turkey: Screening Phytochemicals, Evaluation of Biological Activities, and Molecular Docking Study

    • Authors: Ahmet Altay, Esma Yeniceri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yilmaz, Ekrem Koksal
    • Year: 2022
    • Citation: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202200348

  • Title: Phytochemical Analysis and Biological Evaluation of Hypericum linarioides Bosse: in Vitro and in Silico Studies

    • Authors: Ahmet Altay, Esma Kübra Kağan Yeniçeri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yılmaz, Ekrem Köksal
    • Year: 2022
    • Citation: ChemistrySelect
    • DOI: 10.1002/slct.202200039

William Skelton | Medical Oncology | Best Researcher Award

Published on by NESIN Awards

Dr. William Skelton | Medical Oncology | Best Researcher Award

Assistant Professor of Medicine at University of Virginia Comprehensive Cancer Center, United States

Dr. William Paul Skelton IV is an Assistant Professor of Medicine at the University of Virginia School of Medicine, specializing in Hematology and Oncology. With extensive training from prestigious institutions like Moffitt Cancer Center and the University of Florida, Dr. Skelton is a dedicated clinician and researcher in Genitourinary Oncology. His career is marked by numerous awards, including recognition for excellence in patient care and teaching. Dr. Skelton is committed to advancing cancer treatment through research and has a notable record of impactful publications and presentations in the field. His professional contributions extend to mentoring and serving on various academic committees.

Publication Profile

Education

Dr. William Paul Skelton IV completed his Hematology/Oncology Fellowship at Moffitt Cancer Center, University of South Florida, followed by a Chief Medical Residency at the University of Florida. He earned his Internal Medicine Residency from the same institution and graduated with honors in research from the University of Florida College of Medicine. Dr. Skelton holds a Magna Cum Laude degree in Chemistry from Duke University and a high school diploma with exceptional achievements from King International Baccalaureate High School.

Experience

Dr. Skelton’s professional journey includes his current role as an Assistant Professor of Medicine at the University of Virginia School of Medicine. Previously, he served as a Hematology/Oncology Fellow at Moffitt Cancer Center and as a Chief Medical Resident during his Internal Medicine Residency at the University of Florida. His clinical expertise encompasses Genitourinary Oncology, and he has contributed significantly to medical education through precepting and mentoring medical students, residents, and fellows.

Awards and Honors

Dr. Skelton has received several prestigious awards, including the Moffitt Cancer Center SPOTTED in FellowSHIP patient care Recognition Award in both 2020 and 2021. He was honored with the Florida ACP Chief Resident Award and the UF Senior Resident Medical Student Teaching Award. Additional accolades include the Craig S. Kitchens Outstanding Senior Medicine Resident Award and selection into the Alpha Omega Alpha Honor Society. His academic honors also include Phi Beta Kappa and the Merck Index Award.

Research Focus

Dr. Skelton’s research primarily focuses on Genitourinary Oncology, particularly the therapeutic advancements and molecular mechanisms underlying renal and bladder cancers. His work includes investigating predictive tools for advanced renal cancer and exploring the impact of systemic therapies on cancer progression. Dr. Skelton’s research is aimed at improving patient outcomes through innovative treatment strategies and clinical trials.

Publications Top Notes

  • Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    • Authors: Skelton, W.P., Masur, J., Thomas, J., Jain, R.K., Sonpavde, G.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 💊💉🩺
  • Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus
    • Authors: Ali, S., Fortune, K., Masur, J., Dreicer, R., Skelton, W.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 🩸👨‍⚕️🧬
  • Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer
    • Authors: Altshuler, E., Franke, A.J., Skelton, W.P., Dai, Y., George, T.J.
    • Journal: Clinical Colorectal Cancer
    • Year: 2023
    • Citations: 2 🧬🔬
  • Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
    • Authors: Zhang, Y., Kumar, P., Adashek, J.J., Manley, B.J., Spiess, P.E.
    • Journal: Cells
    • Year: 2022
    • Citations: 6 🧫🔬💊
  • FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    • Authors: Adib, E., El-Zarif, T., Jain, R.K., Choueiri, T.K., Sonpavde, G.P.
    • Journal: BJUI Compass
    • Year: 2022
    • Citations: 6 🧬💉🧪
  • Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
    • Authors: Skelton, W.P., Dahmen, A., Chatwal, M., Chahoud, J., Spiess, P.E.
    • Book Chapter: Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
    • Year: 2022
    • Citations: 0 📖🦠💉
  • Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration
    • Authors: Ravi, P., Pond, G.R., Diamantopoulos, L.N., Grivas, P., Sonpavde, G.P.
    • Journal: BJU International
    • Year: 2021
    • Citations: 13 🧬🌍
  • Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
    • Authors: Starr, J.S., Skelton, W.P., Rahmanian, K.P., George, T.J., Moseley, R.E.
    • Journal: Journal of Palliative Care
    • Year: 2021
    • Citations: 0 📊🩺📋
  • A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
    • Authors: Franke, A.J., Skelton, W.P., George, T.J., Iqbal, A.
    • Journal: Clinical Colorectal Cancer
    • Year: 2021
    • Citations: 4 🧪📊
  • Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    • Authors: Adashek, J.J., Zhang, Y., Skelton, W.P., Manley, B., Spiess, P.E.
    • Journal: Frontiers in Oncology
    • Year: 2021
    • Citations: 5 🧬🩺💉